An Extension Study for Patients Who Participated in the CAMN107X2201 Study



Status:Recruiting
Conditions:High Blood Pressure (Hypertension)
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:3/30/2013
Start Date:January 2012
End Date:November 2016
Contact:Novartis Pharmaceuticals
Phone:862-778-8300

Use our guide to learn which trials are right for you!

An Extension Study to CAMN107X2201 to Evaluate the Long-term Safety Tolerability and Efficacy of Oral Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)


This is an extension study for patients who participated in the CAMN107X2201 study.


Inclusion Criteria:

1. Written informed consent must be obtained from the patient or legal guardian, before
any assessment is performed.

2. Patients who participated in CAMN107X2201 clinical trial and completed the study,
including all end-of-study (Study Completion) assessments of the Week 48 (Day 336) in
Cohort 1 and the Week 24 visit (Day 168) in Cohort 2 of the study protocol.

Exclusion Criteria:

Patients fulfilling any of the following criteria are not eligible for inclusion in this
study:

1. Women of child-bearing potential, defined as all women physiologically capable of
becoming pregnant UNLESS they are using two birth control methods. The two methods
can be a double barrier method or a barrier method plus a hormonal method. Adequate
barrier methods of contraception include: diaphragm, condom (by the partner),
intrauterine device (copper or hormonal), or sponge with spermicide. Hormonal
contraceptives include any marketed contraceptive agent that includes an estrogen
and/or a progestational agent

2. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
female after conception and until the termination of gestation, confirmed by a
positive hCG laboratory test (> 5 mIU/mL)

3. Patients with a pulmonary capillary wedge pressure > 15 mm Hg at time of Study
Completion Assessments in CAMN107X2201. If pulmonary capillary wedge pressure is not
attainable, then a left atrial pressure measurement may be used in its place.

4. Patients with LVEF < 45%

5. Patients with thrombocytopenia, platelet count < 50 x109/L (50 x 103/µL)

6. Patients with uncontrolled systemic arterial hypertension, systolic > 160 mm Hg or
diastolic >90 mm Hg

7. Patients with a QTcF > 450 ms for males and > 470 ms for females in the absence of
right bundle branch block (based on Visit 1 ECG if required to be performed)

8. [In Canada Only: Liver function tests ALT or AST > 1.5 times ULN]

Other protocol-defined inclusion/exclusion criteria may apply.
We found this trial at
8
sites
Knoxville, Tennessee 37934
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
Ann Arbor, Michigan 48109
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Boston, Massachusetts 02118
?
mi
from
Boston, MA
Click here to add this to my saved trials
Cincinatti, Ohio 45219
?
mi
from
Cincinatti, OH
Click here to add this to my saved trials
High Point, North Carolina 27262
?
mi
from
High Point, NC
Click here to add this to my saved trials
Miami, Florida 33136
?
mi
from
Miami, FL
Click here to add this to my saved trials
Phoenix, Arizona 85012
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Rochester, Minnesota 55905
?
mi
from
Rochester, MN
Click here to add this to my saved trials